HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
CompletedNCT01903837

A Study of ALKS 3831 in Adults With Schizophrenia

This study evaluated the safety of Olanzapine for people with schizophrenia.

Medication studyAges 18–50Multiple countries
The study in practice

Understand this study

What did researchers investigate?

This study evaluated the safety of Olanzapine for people with schizophrenia.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.

Listed locations
Little Rock and 60 more locationsSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study clarity

Study information

Study start dateJune 2013
Recruitment status
Completed
Enrollment listed in the registry
347
Sponsor
Alkermes, Inc.
Sponsor type
Other organization
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States, Bulgaria, Czechia
Age range
From 18 Years to 50 Years
Official registry ID
NCT01903837
Official title
Show the full official title

A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine

Looking for a study you can join?

Explore recruiting studies

Get this study by email

HopeStage may email me about this study.
Loading the security check...

Recruitment & locations

Completed

Little Rock, United States · Anaheim, United States · Costa Mesa, United States

55 more locations
  • Culver City, United States
  • Escondido, United States
  • Garden Grove, United States
  • National City, United States
  • Oakland, United States
  • Oceanside, United States
  • Orange, United States
  • Pico Rivera, United States
  • San Diego, United States
  • Torrance, United States
  • New Britain, United States
  • Washington D.C., United States
  • Bradenton, United States
  • Fort Lauderdale, United States
  • Gainesville, United States
  • Kissimmee, United States
  • Leesburg, United States
  • Oakland Park, United States
  • Orlando, United States
  • Atlanta, United States
  • Decatur, United States
  • Chicago, United States
  • Lake Charles, United States
  • Shreveport, United States
  • Rockville, United States
  • Flowood, United States
  • Creve Coeur, United States
  • St Louis, United States
  • Marlton, United States
  • Neptune City, United States
  • Canton, United States
  • Mason, United States
  • Oklahoma City, United States
  • Philadelphia, United States
  • Charleston, United States
  • Memphis, United States
  • Austin, United States
  • Dallas, United States
  • DeSoto, United States
  • Houston, United States
  • Salt Lake City, United States
  • Bellevue, United States
  • Richland, United States
  • Burgas, Bulgaria
  • Kazanlak, Bulgaria
  • Lovech, Bulgaria
  • Novi Iskar, Bulgaria
  • Pazardzhik, Bulgaria
  • Sofia, Bulgaria
  • Tserova Koria, Bulgaria
  • Varna, Bulgaria
  • Vratsa, Bulgaria
  • Brno-mesto, Czechia
  • Prague, Czechia
  • Czechia
Checked Official study record (opens in a new tab)
FAQ

Questions about this study

What did researchers investigate?

This study evaluated the safety of Olanzapine for people with schizophrenia.

Who is behind this study?

The study sponsor is Alkermes, Inc.

Did this study involve medication?

Yes. The study involved medication, including Samidorphan (Low Dose), Samidorphan (Medium Dose), Samidorphan (High Dose), Placebo and Olanzapine.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies